Aegis Capital Downgrades Acadia Pharma (ACAD) to Hold; Sees Nuplazid as Key, but Valuation Now Full
- Wall St opens higher as more earnings roll in
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Needham & Company Affirms Acadia Pharma (ACAD) at 'Buy'; Says Initial Nuplazid Sales Affected by Sampling
August 5, 2016 8:19 AM EDTNeedham & Company affirms Acadia Pharma (Nasdaq: ACAD) at Buy with a price target of $49 following Q2 results on Thursday night.
Analyst Alan Carr commented today, Acadia reported $97,000 in Nuplazid 2Q16 sales, compared to our $0.5M and consensus $0.1M estimates. Mgmt reported that extensive use of sampling programs significantly impacted sales. We expect this to continue into 3Q16 and have adjusted our estimates for... More
Acadia Pharma (ACAD): 2Q Results Don't Capture A Real Indication For NUPLAZID Demand - Piper Jaffray
August 5, 2016 7:37 AM EDTPiper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Acadia Pharmaceuticals (NASDAQ: ACAD) after the company reported 2Q16 earnings, including $97K in NUPLAZID revenues from the first month in-market. Its much too early to dissect the $97K figure, but the analyst is encouraged by managements qualitative feedback on the call around early adoption by movement disorder... More
Acadia Pharma (ACAD) Misses Q2 EPS by 14c
August 4, 2016 4:25 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.63), $0.14 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $97 thousand versus the consensus estimate of $90 thousand.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
... More